Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer.

Abstract

BACKGROUND:

Dexamethasone is administered intraoperatively to prevent anesthesia-related nausea and vomiting and to reduce postoperative opioid administration. However, the adverse effects of corticosteroids on anastomotic healing and wound infection as well as oncologic outcomes remain unclear. We analyzed the effect of intraoperative dexamethasone administration on surgical outcomes after pancreaticoduodenectomy and on long-term survival in pancreatic cancer patients.

METHODS:

A total of 679 pancreaticoduodenectomies from a prospectively maintained database were analyzed. Surgical outcomes were compared between patients who received intraoperative dexamethasone and those who did not. Kaplan-Meier curves and Cox-regression survival analysis were performed in patients with pancreatic cancer. A propensity analysis was done to reduce the inherent bias of retrospective design.

RESULTS:

Patients who received dexamethasone (117, 17.2%) were younger and more likely to be female than those who did not (p = 0.001). Overall and 30-day major morbidity were similar among all resected patients, although there were fewer infectious complications in the dexamethasone group (18.8% vs. 28.5%, p = 0.032). In pancreatic cancer patients, dexamethasone was associated with significantly improved median overall survival (46 vs. 22 months, p = 0.017). This effect occurred independently of stage, pathologic characteristics, or adjuvant therapy, with adjusted hazard ratios, derived from pre-propensity and post-propensity analysis, of 0.67 (0.47-0.97) and 0.57 (0.37-0.87), respectively.

CONCLUSIONS:

A single intraoperative dose of dexamethasone did not increase morbidity after pancreaticoduodenectomy and, in fact, was associated with a decrease in infectious complications. The treatment was independently associated with improved overall survival in patients with pancreatic adenocarcinoma, an effect that cannot be explained and needs further validation in a prospective setting.

• Authors: Marta Sandini, Katarina J Ruscic, Cristina R Ferrone, Andrew L Warshaw, Motaz Qadan, Matthias Eikermann, Keith D Lillemoe, Carlos Fernández-Del Castillo
• Journal: Annals of surgical oncology (Ann Surg Oncol) Vol. 25 Issue 13 Pg. 4020-4026 (Dec 2018) ISSN: 1534-4681 [Electronic] United States
• PMID: 30298316 (Publication Type: Journal Article)

Chemical References

• Glucocorticoids
• Dexamethasone

Topics

• Abdominal Abscess (etiology)
• Aged
• Carcinoma, Pancreatic Ductal (surgery)
• Dexamethasone (therapeutic use)
• Female
• Glucocorticoids (therapeutic use)
• Humans
• Intraoperative Period
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Pancreatic Fistula (etiology, microbiology)
• Pancreatic Neoplasms (surgery)
• Pancreaticoduodenectomy (adverse effects)
• Pneumonia (etiology)
• Proportional Hazards Models
• Retrospective Studies
• Sepsis (etiology)
• Surgical Wound Infection (etiology)
• Survival Rate
• Time Factors
• Urinary Tract Infections (etiology)